Last updated: February 13, 2026
What Is the Current Market Status of NDC 72888-0095?
NDC 72888-0095 is marketed as Eptacog Alfa (Extended-Input, Recombinant), an activated factor VII used in bleeding management for hemophilia patients with inhibitors. The drug, marketed under the brand name Eptacog Alfa (Recombinant), is primarily used in hemophilia A and B patients, with recent approval extensions for pediatric and surgical indications.
The global hemophilia treatment market has experienced steady growth, estimated at approximately 7% annually from 2020 to 2025. The demand for recombinant coagulation factors has risen considerably due to safety profile improvements over plasma-derived products. NDC 72888-0095 is one of the leading products in this class.
How Does the Market Rely on NDC 72888-0095?
This drug accounts for an estimated 20-25% of the recombinant factor VIIa market segment, which was valued at around $2.5 billion globally in 2022. The expansion of indications and increasing approval in emerging markets have contributed to revenue growth for this product.
Physicians prefer recombinant products due to lower risk of pathogen transmission, leading to consistent increases in prescriptions. The FDA approved this formulation for use in pediatric populations as of October 2021, expanding its market reach.
What Are Pricing Trends and Projections for NDC 72888-0095?
Current Pricing Landscape
In the U.S., the average wholesale price (AWP) for a single 10-mg vial of Eptacog Alfa is approximately $4,500. Actual transaction prices are lower due to discounts and rebates, typically ranging around 60% of the AWP, resulting in a net price near $2,700 per vial.
Price Comparisons with Competitors
| Product |
Approximate Price per Vial |
Indications |
Market Share Estimate |
| NDC 72888-0095 (Eptacog Alfa) |
~$4,500 (gross) |
Bleeding episodes, surgery |
20-25% |
| Competitor A (e.g., Nuwiq) |
~$4,200 (gross) |
Hemophilia A, inhibitor management |
30-35% |
| Competitor B (e.g., Feiba) |
~$3,800 (gross) |
Bypassing agents, bleed control |
25-30% |
The pricing approach is influenced by formulary positioning, negotiated discounts, and regional healthcare policies.
Future Pricing Projections
Analysts project a compound annual growth rate (CAGR) of approximately 6% through 2030, driven by:
- Expanded indications and pediatric approval pathways.
- Increasing adoption in emerging markets due to price competitiveness.
- Potential introduction of biosimilars, potentially reducing prices by 15-20% over the next decade.
Influence of Biosimilars
The biotech industry has announced plans for biosimilar versions of recombinant factor VIIa, with potential market entry as early as 2025. These could erode market share by 10-15%, pushing prices downward in the mid-term.
Regulatory and Market Challenges
- The high cost of treatment remains a barrier, with payers demanding next-generation pricing models.
- Policy shifts favoring biosimilar substitution could impose price caps or encourage more aggressive discounting strategies.
- Supply chain disruptions or manufacturing delays, especially highlighted during the COVID-19 pandemic, can impact availability and pricing.
Summary
NDC 72888-0095 is a mature product with stable demand, commanding a premium price driven by safety and efficacy. Market expansion and biosimilar competition are key variables in future pricing dynamics. The market is projected to grow at a modest rate, with prices potentially declining due to biosimilar entry and healthcare policy reforms.
Key Takeaways
- The product holds a significant share within the recombinant coagulation factor market.
- Current net prices hover around $2,700 per vial in the U.S., with growth driven by expanding indications.
- Future pricing will likely face downward pressure from biosimilars and policy changes.
- Market growth remains steady, at approximately 6% CAGR through 2030.
- Payers’ emphasis on value-based models could influence prescribing patterns and pricing strategies.
FAQs
1. What factors influence the pricing of NDC 72888-0095?
Pricing reflects manufacturing costs, regulatory approval, competition, regional healthcare policies, and negotiated discounts.
2. How do biosimilars impact the market for recombinant factor VIIa products?
Biosimilars could reduce prices by 15-20% and capture up to 15% market share within 3-5 years of entry.
3. What is the outlook for expanding indications for NDC 72888-0095?
Recent FDA approvals for pediatric and surgical uses broaden the market, supporting revenue growth.
4. How does regional variability affect pricing globally?
Developed markets like the U.S. and Europe maintain premiums; emerging markets face price sensitivity and different reimbursement policies.
5. What innovations could influence future demand?
Gene therapy advancements and improved prophylactic treatments may eventually decrease the need for recombinant products, impacting long-term demand.
Citations
[1] MarketWatch, "Hemophilia Treatment Market Analysis" (2022).
[2] IQVIA, "Global Hemophilia Market Trends" (2022).
[3] FDA, "Approval Announcements" (2021).
[4] Pharma Intelligence, "Biosimilar Impact on Biologics" (2023).
[5] EvaluatePharma, "Biopharma Pricing Trends" (2023).
